Human IFN-γ T cell ELISPOT kit - 5-plate

SKU
CT230-B5
Complete ELISPOT kit including all reagents (480 determinations).
Format
5-plate
Price
€ 670
Reactivity
Human
Category
T cell ELISPOT
Analyte
IFN-γ
Description
Our ELISPOT kits provide a complete, ready-to-use solution for a reliable, high-performance ELISPOT assays. Each kit includes all essential components: coating and detection antibodies, streptavidin-HRP, TMB substrate, blocking stock solution, dilution buffer, and Tween-20.
Description
IFN-γ is a potent immune regulating cytokine that plays a central role in activating the body’s defense against infections and malignant cells. By enhancing antigen presentation and boosting the activity of T cells and natural killer (NK) cells, IFN-γ drives strong antiviral and anti tumor reponses. It is primarily produced by activated T helper 1 (Th1) cells, cytotoxic T cells, γδ T cells, NK cells, and natural killer T (NKT) cells, making it a key indicator of cellular immune activation in research and diagnostic applications.
Alternative names
IFN-γ, IFN-gamma, IFN-g, IFNg, interferon γ, interferon-γ, interferon-gamma, interferon gamma, INF-g, INF-gamma, immune interferon, Type II interferon
Image
Image

References

Authors, et al. Title Journal Year Volume Pages
Qing-Yuan Yang Age-Related Immunoreactivity Profiles to Diverse Mycobacterial Antigens in BCG-Vaccinated Chinese Population Front Immunol 2020 11 608220
Huiying Liang Clinical manifestation and islet β-cell function of a subtype of latent autoimmune diabetes in adults (LADA): positive for T cell responses in phenotypic type 2 diabetes Acta Diabetol 2019 56 1225-1230
Lijun Liang Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials Cancer Immunol Immunother 2019 68 1467-1477
Irati Zubizarreta Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial Proc Natl Acad Sci U S A 2019 116 8463-8470
David Ostrov Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes J Clin Invest 2018 128 1888-1902
Rhiannon Kundu In silico and ex vivo approaches indicate immune pressure on capsid and non-capsid regions of coxsackie B viruses in the human system PLoS One 2018 13 e0199323
Laurent Gilardin The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope Haematologica 2017 102 1833-1841
Mohammad Ali Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes Sci Transl Med 2017 9 eaaf7779
Yanyan Han Dynamic and specific immune responses against multiple tumor antigens were elicited in patients with hepatocellular carcinoma after cell-based immunotherapy J Transl Med 2017 15 64
Burç Dedeoglu T-Cell Composition of the Lymph Node Is Associated with the Risk for Early Rejection after Renal Transplantation Front Immunol 2017 8 1416